<DOC>
	<DOCNO>NCT01222910</DOCNO>
	<brief_summary>The study conduct open-label , balance , randomize , two-treatment , two-period , two-sequence , single-dose , crossover , bioequivalence study compare valacyclovir hydrochloride tablet 1 gram manufacture OHM Laboratories Inc. NJ 08901 VALTREXÂ® caplets 1 gram manufacture GlaxoSmithKline , Research Triangle Park , NC 27709 healthy , adult , male , human subject fast condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Valacyclovir Hydrochloride Tablets 1gm Under Fasting Condition</brief_title>
	<detailed_description>Following overnight fast least 10 hour , single oral dose valacyclovir hydrochloride 1 gram either test reference investigational product administer period study , along 240 mL drink water ambient temperature low light condition supervision train study personnel . Both test reference product administer study subject , one period ( except subject number 04 , 21 27 drop study ) . During course study , safety parameter assess vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical parameter , serology urine analysis ) baseline . Adverse event monitoring do throughout study . Laboratory parameter hematology biochemistry ( except blood glucose cholesterol ) repeat end study .</detailed_description>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Were age range 1845 year . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . There deviation regard . History known hypersensitivity valacyclovir , related drug like acyclovir drug . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Presence value acceptable limit hemoglobin , total white blood cell count , differential WBC count platelet count . Positive urinary screen test drug abuse ( opiates cannabinoids ) . Presence value acceptable limit serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Clinically abnormal ECG Chest Xray . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological hematological disease , diabetes glaucoma . Inability communicate well ( i.e . language problem , poor mental development , psychiatric illness poor cerebral function ) might impair ability provide , write informed consent . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Use regular medication ( OTC prescription ) 14 day drug metabolize enzyme modifying medication within 30 day prior Day 1 study . Participation clinical trial within 12 week precede Day 1 study ( except subject dropout/withdrawn previous study prior period I dose ) . Subjects , completion study , would donate /or lose 350 ml blood past 3 month study participation . There deviation regard .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Valacyclovir hydrochloride fasting study</keyword>
</DOC>